On Wednesday, Teladoc Health received an upgrade to its Relative Strength (RS) Rating, from 66 to 71.
This exclusive rating from Investor's Business Daily identifies price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 in the early stages of their moves. See if Teladoc Health can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
While Teladoc Health is not near an ideal buy point right now, see if it goes on to form and break out of a proper chart pattern.
The company posted negative growth for both the top and bottom lines last quarter. Teladoc Health is expected to report its next quarterly numbers on or around Feb. 26.
The company earns the No. 9 rank among its peers in the Computer Software-Medical industry group. Doximity, Waystar Holding and Privia Health Group are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
